Inclusion criteria considerations . The inclusion criteria describe potential study participants who can best provide an answer to the clinical research question. Common elements of the inclusion criteria include demographic characteristics, clinical attributes, geographic factors, and temporal considerations. Defining the inclusion criteria can help to maintain a degree of homogeneity among the accessible population and narrow the available pool of eligible study participants. The inclusion criteria should also address the capacity of the participant to understand the study goals, the study requirements (such as completing questionnaires and taking study medications), and the potential risks associated with joining a study.
For example, as shown in the table, the inclusion criteria for the study on the efficacy of fish oil in lowering triglyceride levels in adults with HIV contain an age limitation, since advanced age is associated with an accelerated loss of CD4+ cells and fish oil can reduce CD4+ cell count. 1 A triglyceride parameter (fasting serum triglycerides between 150 and 500 mg/dL) is also required to capture participants with high triglyceride levels, yet such a range necessarily leaves out those with extremely high triglycerides who may otherwise be eligible for prescription fish oil treatment. Additionally, a parameter for participants' CD4+ cell count is necessary to ensure the participants' immune systems are stable.
The possibility that participants will be able to travel easily to the study site is another vital consideration: geographic limitations are essential if virtual study visits are not possible and face-to-face interactions are necessary. An example of a temporal study criterion is the requirement that a participant wait a minimum of six months or more after starting a new HIV drug regimen. The waiting period reduces the likelihood that an elevated triglyceride level is a temporary drug side effect that will return to normal once the proper dosage of the new HIV drug is achieved.
Finally, the informed consent process is also among the inclusion criteria. A future article in this series will discuss the ethics of patient participation, including such issues as the potential for coercion or undue influence and the ability of the study participant to provide verbal and written consent.
Exclusion criteria considerations . The exclusion criteria describe potential study participants who meet the inclusion criteria but have characteristics that could affect the successful outcome of the study or lead to an increased risk of adverse effects. In this way, the exclusion criteria act as a mechanism to reduce potential study risks and confounding variables. 2 Confounding variables may affect the outcome of interest (the dependent variable). For instance, in the example study, the triglyceride level is the dependent variable; since the study is examining the effect of fish oil on reducing triglycerides, potential participants already using fish oil are not eligible to join.
In formulating the exclusion criteria, it's important to consider factors that would increase the likelihood of participants' loss to follow-up or inability to provide necessary data. For instance, participants actively abusing alcohol and illicit drugs were not eligible to join the HIV and high triglycerides study because substance abuse could have limited a participant's ability to comprehend and comply with study requirements. The use of a screening tool such as the Mini-Mental State Examination, which measures attention, recall, and calculation, can be used to exclude participants who score below a certain threshold (in the example study, the threshold was 24). 1, 3 Screening for cognitive impairment in this way may increase the likelihood of obtaining the required data. It's also important to anticipate the high risk of adverse effects related to comorbidities or current treatments. Participants with diabetes mellitus were also excluded from the example study, as fish oil can raise blood glucose levels and may not be safe for some participants.
Practical considerations for designing the eligibility criteria . When formulating the eligibility criteria, it can be helpful for prospective authors of a new clinical research study to review published studies with similar study participants and objectives. Examine the approaches used in such investigations. Assess the data on the retention of the participants and evaluate the reasons for participant loss to follow-up. Much can be learned about the success or potential flaws of study methods from the experiences of researchers in previously conducted studies.
Defining the eligibility criteria requires a delicate balance between restrictive and less restrictive. A restrictive criterion can make participant recruitment and enrollment more difficult by reducing the eligible participant pool. Additionally, a restrictive criterion might increase the time frame required for study completion, as well as the workforce needed to recruit and enroll study participants. On the other hand, a less stringent criterion may make it easier to recruit and enroll participants, which can increase the generalizability of a study's findings; however, it can also result in more confounding variables and an overly heterogeneous participant pool.
Obtaining IRB approval . During the development of the eligibility criteria, review the Code of Federal Regulations Title 45, Part 46 (45 CFR 46), which focuses on the protection of human subjects. 4 Since institutional review board (IRB) approval is mandatory for all clinical research studies, IRBs will assess study protocols to ensure they meet the 45 CFR 46 requirements. The focus of 45 CFR 46 is on the unbiased selection of study participants centered around sex, race, ethnicity, religion, nationality, and other factors. It stipulates that all eligible participants should be considered unless there is a compelling safety or scientific rationale against it. For example, a prostate cancer study can reasonably exclude women, since the disease is specific to men. In another example, a case to exclude pregnant women could be made for studies with known risks to maternal and fetal health.
In writing the eligibility criteria, use bullets or a numbered list. This format makes it easier for IRB review and implementation. A printed (or an electronic) version of the eligibility criteria placed near the telephone, computer, or participant screening area can provide study team members with a copy they can easily review to reduce the chances of enrolling ineligible participants.
Participant recruitment is one of the most challenging aspects of conducting clinical research. It's estimated that a lack of enrollment accounts for delays or cancellations of up to 60% of clinical trials 5 ; therefore, a well-thought-out and feasible recruitment plan is vital.
The study protocol provides details of the procedures the research team will follow to recruit and enroll study participants. In designing the recruitment plan, consider the anticipated participant accrual rate—the number of participants per month or year who are enrolled and meet all study requirements—and how long it will take to complete the recruitment goals. Describing the specifics of how and where to obtain eligible study participants is an essential component of the recruitment plan. The researchers must specify the methods that will be used to find and approach potential study participants and the setting in which they plan to do so, such as a clinic or a research site. For example, in recruiting the study of HIV-positive adults with high triglyceride levels, flyers and brochures were developed and sent to local HIV clinics in the New York City area. 1 Potential participants then called the research center to inquire about the study; in this way, the participants initiated the recruitment process.
Recruitment materials should include the title of the protocol, IRB study number, sponsoring institution, contact information, and purpose of the research (in our example, the purpose was to investigate the use of fish oil as a treatment for HIV-positive adults with high triglyceride levels), and indicate whether study participants will receive compensation for their time and effort. 6 All methods to advertise or promote the study require IRB approval before implementation. Some examples of recruitment materials include the telephone script used to discuss the study with potential participants, as well as flyers, posters, postcards, newspaper advertisements, press releases, website advertisements, electronic mailings, and social media posts. 5, 6 The IRB may require specific information about recruitment materials before granting approval. Most institutions publish their IRB requirements online; to ensure a smoother review process, read the guidelines associated with each IRB institution.
The development of the eligibility criteria is a complex process that can affect participant recruitment, participant enrollment, and study completion. Reviewing the literature for research studies with populations similar to the proposed target population of a study is an excellent way to identify appropriate eligibility criteria. Designing a feasible recruitment plan that includes the selection of a suitable participant pool and developing approaches to recruiting and enrolling eligible participants is critical to implementing a successful study. The next column will discuss sampling design, including probability and nonprobability sampling methods.
Sampling design in nursing research, measurement in nursing research, the architecture of a research study, selection and implementation of outcome measurements, interpretive methodologies in qualitative nursing research.
Student resources, case studies.
Participant and Nonparticipant Observation: A Study of Instructional Support Liaisons
The case presents an example of a research project in which the researchers struggled to negotiate participant and nonparticipant observation roles. The project and the data collection efforts including mistakes and eventual solutions are described. The case presents the benefits and challenges of engaging in participant and nonparticipant observation, specifically for those in the field of education. Finally, this case highlights the importance of thoughtfully selecting one’s role in observational data collection.
1: What are the differences between participant and nonparticipant observation?
2: Why is it important to reflect on the researchers’ roles in participant observation?
Developing and Executing a Data Collection Plan for Archival Research
This case details the process of planning and carrying out archival research on municipal associations, and it discusses the challenges and opportunities that arise from researching an understudied field, including the need to identify, locate, and collect primary data. The case discusses the process of developing a Data Collecting Plan and executing a plan of archival research to conduct original, empirical analysis. By carrying out this process, the researcher found and developed the data needed to carry out mixed-methods research, and to analyse the relationship between municipal associations’ memberships and their behaviour in intergovernmental relations.
1: Why is it useful to develop a data collection plan in archival research?
2: How can documents from archives be used in mixed methods research?
Importance of Adapting to Unexpected Circumstances in Qualitative Data Collection
This case is a reflection on a qualitative research project based on focus groups for evaluating the effectiveness of a sports centre for canoe/kayak in Oklahoma City in the US. The purpose of the project was to make sure that what the centre was doing was actually working. The case highlights the importance of being prepared, anticipating problems, and being flexible enough to overcome unforeseen circumstances.
1: Why is proper planning necessary in qualitative data collection?
2: What are the strengths and limitations of using focus group in this kind of evaluation research?
A Mixed-Method Design for Developing a Measure of Entrepreneurial Openness
This mixed methods case explains the development of the concept and measurement scale of entrepreneurial openness – a personality characteristic that helps to understand the impact of an entrepreneur’s personality on a small firm’s performance. The case describes several procedures that were applied in the scale development process: interdisciplinary literature review, interviews, focus group, pilot study, and two large-scale studies with questionnaires and data analysis for assessing each measures reliability and validity.
1: What are the benefits of a mixed-method design in a scale development process?
2: Why is the combination of different methods useful for assessing and ensuring the reliability and validity of the data?
Warning: The NCBI web site requires JavaScript to function. more...
An official website of the United States government
The .gov means it's official. Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site.
The site is secure. The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.
NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.
Pollock K, Wilson E, Caswell G, et al. Family and health-care professionals managing medicines for patients with serious and terminal illness at home: a qualitative study. Southampton (UK): NIHR Journals Library; 2021 Aug. (Health Services and Delivery Research, No. 9.14.)
Chapter 4 findings: participant demographics.
This chapter presents demographic information about participants in workstreams 1 and 2. Details of participants in workstream 3 are given in Chapter 8 .
Twenty-one BFCGs were recruited over a 15-month period between August 2017 and November 2018. Although we do not know how many information packs were subsequently given or sent to BFCGs, we have recorded that at least 94 information packs were given to 16 different HCP teams to distribute. Over half (12/21) of the participating BFCGs were referred via two hospices engaged with the study. Five were recruited through hospital teams across three hospitals. Two more were recruited via community nursing teams and the final two via community organisations.
Forty HCPs were recruited through a variety of routes over a 16-month period between June 2017 and October 2018. Information about the study was sent directly to key professional contacts, primarily via e-mail, and they were asked to distribute this to their networks. We also employed a snowball sampling technique by asking those interviewed to suggest other suitable HCPs or pass on information packs to colleagues. The Clinical Research Network representative supported engagement with general practices and several were visited to explain the study and leave information packs for both workstreams. We particularly targeted SPC teams, GPs, pharmacists and community nursing teams to obtain a range of perspectives from different professional roles.
Over 136 patient information packs and 103 FCG information packs were provided to 16 different HCP sources. We do not know how many of these were given out. Twenty-two patient cases were recruited over a 15-month period between August 2017 and November 2018. Two patients were subsequently withdrawn: one died before sufficient data could be collected and it emerged, during interview, that the other did not meet the eligibility criteria for the study. Twenty patient case studies were completed. Nine further patients or FCGs expressed an interest in the study, but subsequently died or became too ill to take part. In addition, we are aware of 26 potential patients identified by HCPs and discussed with the research team for eligibility who did not go on to engage with the study. In some instances, the HCP subsequently decided that it was not appropriate to discuss the study, often because of a deterioration in the patient’s condition or family circumstances. In other instances, the patients or FCGs who received information packs decided against taking part and did not contact the researchers.
The 20 completed case study participants were recruited through one of three hospices (9/20), a hospital team such as respiratory (5/20), their GP (3/20), a CN (2/20) or a community organisation (1/20). The central participant in the case could be a patient or FCG, who could then go on to nominate other key people. Nominated individuals were then given information about the study and were asked to take part. We utilised a range of key contacts to recruit patients with conditions other than cancer and, where possible, from diverse or disadvantaged groups.
Twenty-one BFCGs were interviewed (15 women and six men). All were single interviews conducted face to face. Nineteen took place in the participant’s own home and two took place at the university. In relation to the patient, 11 identified as a wife, three as husbands, six as sons or daughters (including two in-laws) speaking about a mother, one was a father and one was a friend. The patients referred to in the BFCG interviews were 12 males and nine females and had a range of diagnoses ( Table 1 ), with many having multiple comorbidities. Of the 13 patients with cancer, there was considerable variety in the types of the disease, and for one patient cancer was not the primary diagnosis. Reflecting the high prevalence of cancer in this group, the majority ( n = 16) of patients in the BFCG accounts had been in receipt of SPC.
Bereaved family caregiver reports of patient diagnoses
We completed 27 interviews with HCPs, including one joint interview and three group interviews, with a total of 40 different participants from different professional roles ( Table 2 ). These were single interviews, usually taking place face to face at participants’ place of work, with four conducted by telephone.
Health-care practitioner participation by role
The workstream 2 case studies included several different data sources ( Table 3 ).
Case study data collection
Fifteen of the 20 cases had patient participants who took part to a variable extent, depending on their health and abilities. Each of the 20 cases had between one and five participants, involving 48 separate participants ( Table 4 ). In four cases, the patient was the only participant, and in two other cases the FCG was the only participant. Fourteen HCPs were involved in 11 cases, with 11 of those participating in interviews and three in observations. Patients and FCGs reported that patients often had a number of conditions and it was not always possible to identify their primary diagnosis ( Table 5 ).
Case study participants
Main diagnoses of patients reported in case studies
Across all 20 case studies, a total of 54 interviews were conducted with patients, family members, friends and HCPs. FCGs were predominantly wives, but also husbands, siblings, sons, daughters and, in one case, a friend. HCP participation in the case studies included six HCWs/support workers, four consultants, two GPs, two clinical nurse specialists (CNSs) and one specialist palliative care nurse (SPCN). All interviews with case patients and FCGs took place at their home. Fifteen interviews were conducted as joint interviews with the patient and FCG (four with two FCGs present). In one interview, a HCW was also present. One patient chose to participate solely by telephone throughout their engagement with the study. Two follow-up FCG interviews were conducted by telephone. Three of the 11 interviews with HCPs were carried out by telephone. All others took place at the participants’ place of work. The average duration of data collection for each case, excluding review of medical records, was just under 4 months.
Over the period of case study data collection, 11 observations were carried out with 10 case participants. The specific length of time spent on each observation was not recorded, but ranged from a few minutes to almost 2 hours. Observations were predominantly undertaken during visits to interview participants. Two were undertaken at outpatient appointments. These included observations of:
With consent, photographs were taken as part of data collection in 13 of the cases. Participants gave an overarching written consent to allow photographs to be taken, and verbal consent was then used to check for each individual photograph once an item of interest was identified. Where a participant expressed an interest, they were also shown the photograph to check that they were happy with the content. These were visual ways to document medication storage, medication devices and equipment and to illustrate their impact on the space and environment of the home. They include pictures of dosette boxes, blister packs, personal storage boxes, locations of medication storage (e.g. kitchen cupboard), mobile telephone applications, alarms, non-invasive ventilation and oxygen machines, and equipment such as hospital beds, hoists and a lift installed in a living room. All photographs (see Figures 7 – 17 and Box 2 ) used in this report have been anonymised to remove both patient- and pharmacy-identifying data and each has been reproduced with permission from copyright holders Eleanor Wilson and Glenys Caswell (University of Nottingham, 21 January 2021).
Case study participant ecograms were completed during interviews, where appropriate, and subsequently included in diagrammatic summaries of each case compiled by the researchers on the basis of all data available within each case (see Appendix 1 ).
The largest network included 32 links and the smallest network included nine links (mean, n = 22 links; median, n = 20 links). Key caregivers or links were identified as individuals or services of particular emotional and/or practical importance to the case participants (indicated by dark colours in the ecograms in each case summary in Code Key – for case summaries). The number of key informal caregivers within each network was between zero and two, with two cases recording no informal caregivers as ‘key’. Key formal caregivers ranged from zero to four, with seven cases considered to have no key formal caregivers. Thirteen out of 20 cases had accessed SPC by the end of the study. In five cases, SPC links featured as key caregivers eight times. The most frequent formal caregiver link was with GPs ( n = 7) and the most cited informal caregiver link was a wife ( n = 10). Spouses in total were the most common key informal caregivers (13/20). Where HCWs were in place, they were always seen as key to care (four cases). Disease-specific CNSs were identified as key in three cases and DNs in two.
Given the considerable time that sometimes elapsed between the completion of case interviews and the records review, we felt that it was appropriate to check consent given by patient participants at the start of the study. In five of the cases, there was no patient participant and in one other case the patient had refused consent. We deemed three further patient cases unsuitable to contact, either because we were aware that the patient had died or because the research team felt that it was inappropriate to make further contact. This left 11 cases for which consent had originally been given that needed to be checked. We endeavoured to follow up on each of these cases and to establish GP contact details to undertake reviews. Where the patient had died (in three cases), we discussed this with their FCG and each wanted to support the patient’s initial decision. One patient decided to revoke his initial consent. In two further cases, we were not able to contact the participant to confirm consent. This left eight participants with records that to review, two of whom also had hospice records that we were able to access ( Figure 6 ).
Process of reviewing patient records.
Initially, we had intended to search for differences in the experience of care between patients who had and patients who had not been referred to SPC. For the purposes of the study, the term SPC covers access to SPCNs, consultants and hospices. In practice, however, we found that this distinction was not particularly useful. In part, this was because of the very diverse conditions affecting patients, as well as the different stages of their illness and natural variation between these. All but three of the patient cases survived past the end of the study and would likely be referred for palliative care at a later stage of their illness. Consequently, we have not considered quality or experience of care in terms of a contrast between ‘specialist’ and ‘generalist’. All patients in workstreams 1 and 2 who were affected by cancer and half of those with other conditions had been referred for SPC. Some patients without cancer reported having prolonged input from specialist teams, including those dealing with long-term conditions, respiratory specialists and disease-specific nurses who had considerable experience and expertise in palliative and end-of-life care [e.g. nurses specialising in Parkinson’s disease, COPD, renal disease and motor neuron disease (MND)]. The most significant resource available to patients was the establishment of a key caregiver relationship with a particular HCP, and this resource was drawn from a wide range of general and specialist roles.
However, the established association between cancer and palliative care was apparent in the study data. Based on primary diagnosis, all four cancer patients in the case studies had prolonged hospice stays, outpatient appointments and SPC nursing at home. In comparison, for respiratory disease (e.g. COPD and emphysema), only one of four patients reported access to SPC. Several of these patients described a pattern of bypassing community professionals and contacting emergency and ambulance services directly when they recognised onset of an acute exacerbation of their condition that they anticipated from past experience would require hospitalisation. Three patients with MND had some access to SPC. The experiences of those with conditions such as heart failure, progressive supranuclear palsy (PSP), renal failure or multiple comorbidities all varied. In total, 13 out of our 20 cases reported accessing SPC at some level during their involvement in the study. The majority of BFCGs reported SPC input for their relatives prior to death in a group in which most patients were affected by cancer. The care of some patients in both workstreams had been predominantly managed by GP and DN teams.
Do not attempt cardiopulmonary resuscitation (DNACPR) status was not routinely discussed during the interviews and it was not often mentioned in the BFCG interviews (6/21). However, from the cases for which we have been able to draw on multiple sources of data, we know that 12 patients had a DNACPR in place and two had some form of advanced directive (one with and one without a DNACPR).
Thirteen of the BFCGs reported that the patient had been prescribed AMs. In six instances, these were reported to have been used. Six of the case study participants also reported that AMs were in place. This number is likely to have increased as more of the participating case patients reached the end of life. A further four case study patients held a prescription for ‘just in case’ or ‘rescue’ antibiotics for chest infections. Across both groups, there did not appear to be any association between having anticipatory medications in place and having access to SPC.
Ten of the patients described in the BFCG interviews had a syringe driver put in place for symptom management at the end of life. All but two of these patients had a diagnosis of cancer. Three of the case study patients also had syringe drivers in place. Two of these patients had cancer and one had renal failure. Across both groups, all of the patients recorded to have syringe drivers also had SPC input.
Within the 20 patient cases a total of 222 prescribed items were identified. Appendix 2 provides a list of all of the medication prescribed, as reported by participants or found in medical notes. We were able to review the medical notes of eight patients and in the other 12 we relied on participants’ accounts. Supporting information was also obtained in some interviews with HCPs who had immediate access to medical notes. On average, case patients had just under 12 prescribed medications and this ranged from 6 to 20. These include equipment and machines, such as oxygen concentrators, non-invasive ventilation and nebulisers, creams, eye drops, supplements (e.g. vitamins and fortifying drinks), laxatives and anticoagulants. There were a range of formulations prescribed, including tablets, liquids, injections, inhalers and patches. Complementary medicines were mentioned by participants, but not often and we did not enquire specifically about their use.
The aim of Appendix 2 is to illustrate the number, complexity and range of prescribed items across a relatively small cohort of 20 patients. The data show that participants frequently had more than one medication prescribed from a certain group of medications. Opioid analgesics were the most frequently prescribed medications, followed by proton pump inhibitors, which reduce acid in the stomach and are often prescribed to manage the side effects of other medications in palliative care.
We do not have extensive knowledge of the medications used by the relatives of BFCG participants and we have not attempted to collate this. Information was accessed during a single interview and based on participants’ recall of past events. However, some BFCGs gave very detailed accounts based on meticulous records maintained during the patient’s illness. The researchers were sometimes shown prescription and medicine lists. We cannot, of course, know how medications were taken by patients and whether or not they were taken as prescribed.
This chapter has presented background information on the participants who took part in the study and the different sources and extent of data collected. It includes a summary of the process of recruitment, characteristics of participants in workstreams 1 and 2, their involvement with SPC and the medications prescribed for case study patients. The next chapter gives a detailed account of a single case as a way of understanding the experience of treatment and decision-making at the end of life and to provide context for the key themes and issues presented in the chapters that follow.
Other titles in this collection.
Your browsing activity is empty.
Activity recording is turned off.
Turn recording back on
Connect with NLM
National Library of Medicine 8600 Rockville Pike Bethesda, MD 20894
Web Policies FOIA HHS Vulnerability Disclosure
Help Accessibility Careers
In order to continue enjoying our site, we ask that you confirm your identity as a human. Thank you very much for your cooperation.
A new CEO considers changes to her top team.
The newly appointed CEO of Highstreet Properties has doubts about several members of the top team she has inherited. She’s trying to drive a turnaround, the company has a complicated matrix structure, and some team members seem opposed to her strategy. She’s debating replacing several of them, but she’s worried about making too many changes too quickly, upsetting her board, and bringing in too many former colleagues.
Shannon Levy, the new CEO of Highstreet Properties, stared out the window of the company’s London headquarters, wondering whether she should call Justin Mooney and fire him. A once-thriving developer of retail malls, Highstreet had been battered by consumers’ shift to e-commerce, Covid-19 mall closures, and internal discord over strategy. Shannon had been brought in to turn the business around. She was fast approaching her 100-day mark and already feeling behind on selecting, aligning, and motivating her senior leadership team.
Official websites use .gov
A .gov website belongs to an official government organization in the United States.
Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.
In 1932, the USPHS, working with the Tuskegee Institute, began a study to record the natural history of syphilis. It was originally called the “Tuskegee Study of Untreated Syphilis in the Negro Male” (now referred to as the “USPHS Untreated Syphilis Study at Tuskegee”). The study initially involved 600 Black men – 399 with syphilis, 201 who did not have the disease. Participants’ informed consent was not collected. Researchers told the men they were being treated for “bad blood,” a local term used to describe several ailments, including syphilis, anemia, and fatigue. In exchange for taking part in the study, the men received free medical exams, free meals, and burial insurance.
The U.S. Public Health Service (USPHS) engages the Tuskegee Institute in Macon, AL in the USPHS Tuskegee Untreated Syphilis Study. 2
Penicillin becomes treatment of choice for syphilis , but men in study are not treated.
First news article about the study.
The study ends , on recommendation of an Ad Hoc Advisory Panel convened by the Assistant Secretary for Health and Scientific Affairs.
President Clinton issues a formal Presidential apology .
By 1943, penicillin was the treatment of choice for syphilis and becoming widely available , but the participants in the study were not offered treatment.
In 1972, an Associated Press story about the study was published. As a result, the Assistant Secretary for Health and Scientific Affairs appointed an Ad Hoc Advisory Panel to review the study. The advisory panel concluded that the study was “ethically unjustified”; that is, the “results [were] disproportionately meager compared with known risks to human subjects involved.” In October 1972, the panel advised stopping the study. A month later, the Assistant Secretary for Health and Scientific Affairs announced the end of the study. In March 1973, the panel also advised the Secretary of the Department of Health, Education, and Welfare (HEW) (now known as the Department of Health and Human Services) to instruct the USPHS to provide all necessary medical care for the survivors of the study. 1 The Tuskegee Health Benefit Program (THBP) was established to provide these services. In 1975, participants’ wives, widows and children were added to the program. In 1995, the program was expanded to include health, as well as medical, benefits. The last study participant died in January 2004. The last widow receiving THBP benefits died in January 2009. Participants’ children (10 at present) continue to receive medical and health benefits.
Later in 1973, a class-action lawsuit was filed on behalf of the study participants and their families, resulting in a $10 million, out-of-court settlement in 1974.
On May 16, 1997, President Bill Clinton issued a formal Presidential Apology for the study.
1 “HEW News” Office of the Secretary, March 5, 1973; Memorandum “USPHS Study of Untreated Syphilis (the Tuskegee Study; Authority to Treat Participants Upon Termination of the Study,” from Wilmot R Hastings to the secretary, March 5, 1973.
2 Vonderlehr, R.A., Clark, T., Wenger, O.C., Heller, J.R., Untreated Syphilis in the Male Negro, Journal of Venereal Disease Information. 17:260-265, (1936).
The content here can be syndicated (added to your web site).
BMC Women's Health volume 24 , Article number: 353 ( 2024 ) Cite this article
Metrics details
The SCHUMANN study evaluated the efficacy and safety of the selective P2 × 3 antagonist eliapixant in patients with endometriosis-associated pelvic pain (EAPP).
SCHUMANN was a randomized, placebo- and active comparator-controlled, double-blind to placebo and open-label to comparator, parallel-group, multicenter, dose-finding phase 2b study. The participants were women with surgically diagnosed endometriosis who fulfilled defined EAPP criteria. Participants were randomized 1:1:1:1 to twice daily (BID) 25 mg, 75 mg, or 150 mg oral eliapixant or a placebo for 12 weeks. An exploratory once-daily elagolix 150 mg treatment group was also included. The primary endpoint was the absolute change in mean worst EAPP from baseline to the end of intervention (EOI).
Overall, 215 participants were randomized for treatment (44 to eliapixant 25 mg, 44 to eliapixant 75 mg, 43 to eliapixant 150 mg, 43 to a placebo, and 41 to elagolix 150 mg). For safety reasons, the study was terminated early; both treatment and enrollment stopped immediately, producing less than 50% of the planned number of completers. The study found no significant differences in EAPP reduction from baseline between groups and no significant dose-response model. The elagolix 150 mg group showed better pain reduction than any of the other groups. No new safety signals were observed, relative to the previously known safety profile of eliapixant, which was generally well tolerated. However, one case of moderate and probably drug-induced liver injury in a participant receiving eliapixant 150 mg BID supported the association between eliapixant and a potential increase in liver function values, defined before the start of the phase 2 program.
This study did not meet its primary objective as no statistically significant or clinically relevant differences in changes of mean worst EAPP from baseline were observed between treatment groups. The single observed case of moderate, probably drug-induced liver injury was the second case in the eliapixant phase 2 program conducted in the following indications: refractory or unexplained chronic cough, diabetic neuropathic pain, overactive bladder, and EAPP. Due to this, the benefit-risk ratio for the study was no longer considered to be positive.
ClinicalTrials.gov identifier NCT04614246; registered November 3, 2020.
Peer Review reports
Endometriosis is a chronic, benign, sex-hormone-dependent inflammatory disease, characterized by the presence of endometrium-like tissue outside the uterine cavity [ 1 , 2 , 3 , 4 ] and causing a substantial burden to individuals and society [ 5 , 6 , 7 ]. Although its precise prevalence is unknown, estimates range from 1% to 15% within the general female population [ 5 , 8 , 9 , 10 ]. Endometriosis is characterized by pain (primarily chronic, non-menstrual pelvic pain [NMPP]), pain during menstruation (dysmenorrhea) and sexual intercourse (dyspareunia), and infertility. The burden of the disease and the limitations of currently available treatment modalities have created a serious unmet medical need.
P2X3 is a non-selective cation channel activated by adenosine triphosphate (ATP); it has been described as a prominent mediator of pain [ 11 ]. P2X3 receptors are predominantly localized on primary sensory afferent neurons in small-to-medium diameter C and Aδ fibers throughout the body [ 11 , 12 , 13 ], which carry nerve impulses from sensory stimuli toward the central nervous system [ 12 , 14 ]. Afferent neuronal hypersensitization via P2X3 receptor signaling plays a significant role in the pathways that trigger cough and bladder urgency and may influence the pathophysiology of endometriosis-associated chronic pain, overactive bladder (OAB), and diabetic neuropathic pain (DNP) [ 13 , 15 , 16 , 17 , 18 , 19 ].
The expression of P2X3 receptors is upregulated during inflammation; this has been shown to sensitize peripheral nerves and contribute to central sensitization. Sensory nerve fibers within endometriotic lesions can themselves release inflammatory mediators (such as ATP, substance P, and nerve-growth factor) through a process known as neurogenic inflammation, which is thought to play a critical role in endometriosis-associated pain [ 20 , 21 , 22 , 23 , 24 ]. P2X3 expression in both endometriotic endometrium and lesions has been shown to be significantly higher than that found in control endometrium and positively correlated with pain. P2X3 channels are activated by ATP, which is released in response to various stimuli, including tissue injury, mechanical stress such as movement and distension, and the inflammation present in endometriotic lesions, particularly during menstruation [ 25 , 26 , 27 , 28 ]. Antagonizing P2X3 receptors was expected to combine high levels of pain relief with disease modification via an innovative mechanism.
Eliapixant is a potent P2X3 receptor antagonist that preferentially blocks the homomeric P2X3 channel. In a rat neurogenic inflammation model, eliapixant demonstrated robust efficacy in blocking inflammation of the skin evoked by an injection of mustard oil into the uterus and a concomitant transduction of the inflammation via the nervous system (i.e., neurogenic inflammation). It showed significant efficacy on visceral pain in a rat dyspareunia model and was still present 1 week after treatment, suggesting that eliapixant demonstrated efficacy beyond direct analgesic effects.
The goal of this project was to develop eliapixant as non-hormonal treatment for moderate-to-severe pain associated with endometriosis in women of reproductive age. Eliapixant was expected to provide clinical efficacy in the long-term management of pain associated with endometriosis, including a clinically meaningful reduction in chronic pelvic pain, dysmenorrhea, and dyspareunia, with a safety profile suitable for long-term use. It was also expected to improve patients’ quality of life substantially. At the start of this phase 2 study, these anticipated beneficial effects had not yet been demonstrated in patients with endometriosis-related pain. The phase 2b SCHUMANN study aimed to identify the optimal dose of eliapixant in patients with EAPP, to further assess efficacy, and to characterize the safety and tolerability profile of eliapixant over 12 weeks. Eliapixant has been developed in the indications OAB, refractory or unexplained chronic cough (RUCC), and DNP.
SCHUMANN (ClinicalTrials.gov NCT04614246) was a randomized, double-blind, open for active comparator, parallel-group, multicenter, phase 2b study to assess the efficacy and safety of three different doses of eliapixant (BAY 1817080) vs. placebo twice daily (BID) and elagolix 150 mg once daily in women with symptomatic endometriosis conducted at 144 centers in 20 countries across Europe, North America, China, and Japan (see Supplemental Methods for further details). The study comprised a 28-day screening phase, a 35-day pre-intervention period, an 84 + 3-day period of double-blind intervention, and a follow-up period lasting 38/90 days. When the protocol amendment was filed due to study termination, a comprehensive safety follow-up was implemented; this consisted of two additional visits for laboratory safety testing and a required 90-day follow-up for all participants, apart from those randomized to elagolix 150 mg (Supplemental Fig. S1 ). The latest version of the study protocol, including amendments and the statistical analysis plan, is available on ClinicalTrials.gov.
Eligible participants were centrally randomized 1:1:1:1:1 by the sponsor, using an interactive web response system (IWRS), to receive one of three oral doses of eliapixant BID (25 mg, 75 mg, or 150 mg; Bayer AG, Berlin, Germany), a placebo, or elagolix 150 mg once daily (QD). No participants from Japan or China were randomized to elagolix. To maintain blinding, tablets containing the placebo were identical in size, color, and shape to those containing eliapixant.
In addition to the study drugs described above, participants were only allowed to use standardized rescue medication (i.e., ibuprofen, acetaminophen, and tramadol) for treatment of endometriosis-associated pain. Women interested in participating in the study had to stop intake of hormonal treatments. Long-acting hormonal contraceptives as well as gonadotrophin-releasing hormone (GnRH) agonists, - GnRH antagonists, and progesterone receptor modulators had to be stopped at least 28 days before screening; all other hormonal therapies had to be stopped at Visit 1.
The Institutional Review Board/Independent Ethics Committee at each center approved the protocol. The study was carried out in accordance with Good Clinical Practice guidelines, the Declaration of Helsinki, and the International Ethical Guidelines of the Council for International Organizations of Medical Sciences. All participants provided written informed consent.
The investigators enrolled women aged ≥ 18 years with endometriosis surgically diagnosed between 10 years and ≥ 8 weeks before screening and with self-reported moderate-to-severe pain. During the screening period, potential participants made at least 24 daily entries in an endometriosis symptom diary (ESD [ 29 ]), using the daily numeric rating scale (NRS) to indicate ESD item 1a (“worst pain”) summing up to ≥ 98. In Japan, inclusion by clinical diagnosis as opposed to surgical diagnoses was acceptable for up to 50% of the participants. Full inclusion and exclusion criteria are included in the Supplementary Methods .
Patient-reported outcome (PRO) assessments were collected using an electronic handheld diary (eDiary); pain catastrophizing and painDETECT scores were collected via paper questionnaires (see Supplemental Methods ). Safety was monitored throughout the study (adverse events [AEs], clinical laboratory, and vital signs). Two questions on hair and eye color, previously associated with endometriosis and potentially useful in marking genetic subpopulations, were included among the baseline characteristics [ 30 , 31 ].
The primary efficacy endpoint was the absolute change in mean worst EAPP (i.e., ESD item 1, measured daily via the NRS) from baseline to end of intervention (EOI). Other pre-specified endpoints included absolute change in mean worst EAPP from baseline to the first 4/8 weeks of intervention; absolute change in mean worst EAPP on bleeding and non-bleeding days from baseline to the first 4/8 weeks of intervention/EOI (measured via NRS by items 1 and 4 [i.e., intensity of vaginal bleeding, measured daily using a categorical response scale with five levels of increasing intensity: none, spotting, light, normal, heavy] of the ESD), item level, total and/or domain scores at screening, baseline, and Weeks 4/8/EOI and absolute change from baseline, as applicable, using the data collected by PROs (see Supplemental Methods ) and absolute change in mean worst EAPP (overall, during, and outside days with vaginal bleeding) from EOI to non-overlapping, consecutive 28-day intervals during follow-up.
Treatment-emergent AEs (TEAEs) and serious AEs were recorded in line with the Medical Dictionary for Regulatory Activities (MedDRA), version 25.0. Additional safety assessments are described in the Supplemental Methods . At the end of the study, participants who spontaneously reported a taste-related AE completed an assessment on taste disturbances.
A multiple comparison procedure modeling (MCP-Mod) approach [ 32 ] was used to complete a pre-specified analysis of the primary efficacy endpoint. As SCHUMANN was a phase 2b dose-finding study, the MCP-Mod approach, a well-accepted dose-finding method that uses available data more efficiently than traditional pairwise comparisons, was adopted [ 33 , 34 ]. The MCP-Mod approach makes it possible to estimate a dose response and to select an optimum dose for further phase 3 trials [ 34 ].
To detect a dose–response signal, four candidate dose–response models were tested with a single contrast test using the generalized MCP-Mod approach. The null hypothesis (“the response to all doses is equal”) was tested against the alternative (“there is a dose–response relationship”). If at least one of the four individual model tests was statistically significant (adjusted p of one-sided test ≤ 0.1), a dose–response signal would be established. The model with the best fit would then be used to estimate the dose–response curve and minimum effective dose. For further information on the primary endpoint analysis, see the Supplementary Methods .
Sample size calculations were conducted to establish evidence of a drug effect across the doses. A sample size of 50 evaluable participants per dose group was predicted to have approximately 90% power to demonstrate a dose–response relationship for the primary efficacy endpoint, using a one-sided test at a type I error rate of α = 0.10 (see Supplementary Methods for more details).
The secondary endpoint analyses and definitions of the per-protocol as well as the full- and safety-analysis sets are described in the Supplementary Methods .
A statistical evaluation was performed using SAS software version 9.4 (SAS Institute, USA) and ValidR software version 3.5.2 or higher (Mango Solutions, UK). Confirmatory p -values are reported for the analysis of the primary endpoint. The study was not powered to make individual pairwise comparisons between dose groups. The analyses of secondary endpoints, sensitivity, and AEs should be viewed as exploratory.
In total, 504 participants were screened between 01/29/2021 and 01/27/2022, of whom 215 were randomized to eliapixant 25 mg ( n = 44), 75 mg ( n = 44), 150 mg ( n = 43), placebo ( n = 43) (all BID), or elagolix 150 mg ( n = 41) (Fig. 1 ). Follow-up continued until 05/03/2022. Although all 215 randomized participants were included in the full-analysis set, 25 did not receive a study intervention; thus, the safety-analysis set includes 190 participants. A total of 183 participants were included in the per-protocol set (for a definition see Supplemental Methods ). In total, 120 participants (42.7%) completed the treatment period.
Participant disposition. BID twice daily, FAS full-analysis set, SAS safety-analysis set
Table 1 presents an overview of per-protocol set demographic characteristics. Similar results were obtained in the full-analysis set. Age and body mass index (BMI) were generally well balanced across the treatment arms (Table 1 ). The mean (standard deviation [SD]) age was 34.64 (7.22) years, with 26.8% of participants aged < 30 years, 50.3% aged 30–40 years, and 23.0% aged > 40–55 years. The mean (SD) BMI was 25.54 (5.89) kg/m 2 . In the per-protocol set, 73.8% of participants were white. In the elagolix 150 mg arm, however, 94.6% were white, as participants from Japan and China could not be randomized to elagolix (Table 1 ).
Baseline demographics and clinical characteristics were generally well balanced across the treatment groups (Table 1 ). Slight imbalances between the treatment groups were observed in relation to mean worst pain, NMPP, and dysmenorrhea. The mean (SD) of mean worst pain, NMPP, and dysmenorrhea was higher in the eliapixant 150 mg BID arm (6.63 [1.62], 6.45 [1.78], and 7.38 [1.39]), respectively, and in the elagolix 150 mg arm (6.38 [1.78], 6.18 [1.86], and 7.29 [1.84]), respectively, than in other arms (Table 1 ).
Slight imbalances between the treatment groups were also observed with regard to hair and eye color. As expected, given the participating countries, about half of the population (48.6%) had brown eyes. However, the proportion ranged between 35.1% in the elagolix 150 mg arm, which had predominantly white participants (no women from China or Japan were randomized to this treatment group), and 62.2% in the eliapixant 25 mg group. The full-analysis set results were similar.
The data for the primary efficacy endpoint, absolute change in mean worst EAPP from baseline to EOI (measured daily on the NRS as ESD item 1) are shown in Table 2 .
At Week 12, the end of the intervention, the mean (SD) changes in mean worst EAPP from baseline were − 1.56 (1.35) in the eliapixant 25 mg BID arm, − 2.12 (2.66) in the eliapixant 75 mg BID arm, − 1.88 (2.03) in the eliapixant 150 mg BID arm, and − 1.89 (1.91) in the placebo arm, based on the primary per-protocol set. The full-analysis set results were similar. For elagolix, the open-label comparator arm, the mean (SD) of mean worst EAPP was 6.38 (1.76) at baseline and 3.39 (2.57) at Week 12 (EOI), resulting in a mean (SD) change from baseline of − 2.83 (2.38), based on the full-analysis set.
The least squares (LS) mean (standard error [SE]) of change obtained via mixed-model repeated measures from baseline to Week 12 (EOI) was − 1.63 (0.38) in the eliapixant 25 mg BID arm, − 2.13 (0.41) in the eliapixant 75 mg BID arm, − 1.96 (0.41) in the eliapixant 150 mg BID arm, and − 1.94 (0.38) in the placebo arm. Overall, no significant differences were observed across the various treatment arms.
At Week 12 (EOI) the adjusted p -values for the Emax 1, Emax 2, SigEmax 1, and SigEmax 2 candidate models were 0.5266, 0.4679, 0.4052, and 0.4082, respectively. No significant dose-response model was found (Fig. 2 ).
The dose response model and target dose for the change over 28 days indicate the change in worst EAPP from baseline to Week 12 (with 80% CI). Left: Emax model; right: SigEmax model. CI confidence interval, EAPP endometriosis-associated pelvic pain
A secondary analysis on the primary per-protocol set, including the elagolix arm, resulted in similar LS mean changes from baseline for the placebo and eliapixant arms, but showed an LS mean change (SD) from baseline of − 2.69 (0.41) for the elagolix arm, resulting in a difference of approximately − 0.8 from the placebo. This difference is comparable to the effect of elagolix 150 mg QD observed in previous studies [ 35 ]. The mean EAPP on bleeding days was higher at baseline than the overall EAPP, with a mean (SD) of 7.19 (1.62) across all treatment groups and a change from baseline ranging from − 1.07 (1.7) to − 1.73 (2.1), a smaller effect than those observed for overall EAPP. Mean EAPP on non-bleeding days was slightly lower at baseline than overall EAPP, with a mean (SD) of 6.00 (1.87) across all treatment groups and a change from baseline similar to that observed for overall EAPP. No relevant dose–response relationship was observed for any of these endpoints.
Throughout the entire study, participants were asked to report pain at its worst during the past 24 h on a 0–10 NRS on the eDiary to assess dyschezia and dysuria. At baseline, dyschezia mean worst pain was present across all treatment groups with a mean (SD) of 3.78 (2.89), and the means (SDs) in the different treatment groups ranging from 3.04 (2.83) in the eliapixant 25 mg BID group to 4.15 (2.68) in the elagolix 150 mg group. After 12 weeks of treatment, a reduction was observed in all treatment groups, with mean (SD) changes from baseline of − 0.65 (0.81) in the eliapixant 25 mg BID group up to − 2.18 (1.95) in the elagolix 150 mg group. Dysuria mean worst pain at baseline was observed with an overall mean (SD) of 2.80 (2.79), ranging from 2.37 (2.82) in the eliapixant 25 mg BID group to 3.40 (2.78) in the elagolix 150 mg group. After 12 weeks of treatment, a reduction was observed in all treatment groups, with mean (SD) changes from baseline of − 0.67 (1.11) in the eliapixant 25 mg BID group up to − 1.67 (2.01) in the elagolix 150 mg group. No dose-response trend and no relevant difference to placebo were observed for dyschezia or dysuria in the different eliapixant groups.
A higher percentage of participants experienced TEAEs in the eliapixant 150 mg BID arm (76.3% [ n = 29]), placebo arm (73.0% [ n = 27]), and elagolix 150 mg arm (73.7% [ n = 28]) than did so in the other two lower-dose eliapixant treatment arms (eliapixant 25 mg BID (59.0% [ n = 23]) and eliapixant 75 mg BID (55.3% [ n = 21]). The same pattern was seen in the percentage of participants with TEAEs attributed to study intervention (Table 3 ). No AEs/TEAEs had death as an outcome. Few participants had serious TEAEs (Table 3 ). Two serious TEAEs were assessed as related to the study intervention: one in the eliapixant 150 mg BID arm (MedDRA preferred term [PT] “Liver function test increased”) and one in the elagolix 150 mg arm (MedDRA PT “Hypertensive crisis”). A low percentage of participants stopped using the study drug permanently due to a TEAE (Table 3 ).
Table 4 summarizes the most commonly reported TEAEs in each treatment arm, with headache being the most frequently reported TEAE across all treatment arms. In almost all safety-analysis set participants, the maximum intensity of TEAEs was assessed as either mild (43.7%) or moderate (20.0%). Only 7 participants reported severe TEAEs: 3 participants in the eliapixant 150 mg arm, 2 participants in the placebo arm, and 2 participants in the elagolix 150 mg arm.
Most TEAEs attributed to study intervention affected single participants and were assessed as having either mild or moderate maximum intensity. The TEAEs attributed to study intervention and reported by at least 2 participants were as follows:
In the eliapixant 75 mg BID arm: 2 participants reported intermenstrual bleeding.
In the eliapixant 150 mg BID arm: 2 participants reported dysgeusia, 2 participants reported taste disorder, and 3 participants reported hypogeusia.
In the elagolix 150 mg arm: 2 participants reported headache and 6 participants reported hot flushes.
For 1 participant in the placebo arm (PT: “Nightmares”) and 2 participants in the elagolix 150 mg arm (PT: “Hot flushes”, PT: “Hypertensive crisis”), TEAEs attributed to study intervention were assessed as severe at maximum intensity.
Ten taste-related AEs were reported in the eliapixant 150 mg BID (6 participants, 15.8%; one of those reported three events) and placebo arms (2 participants, 5.4%). Eight of the 10 taste-related AEs were attributed to the study medication and impacted participants in the eliapixant 150 mg arm. No participant discontinued treatment due to a taste-related AE.
Increases in liver function parameters and antithrombin III activity were described as potential risks in the study protocol and monitored closely across the study period. No mean increase over time or relevant differences were observed across the treatment arms in relation to the mean values of aspartate aminotransferase (AST), alanine aminotransferase (ALT), gamma-glutamyl transferase (GGT), or bilirubin. However, a dose-dependent increase in the mean values of alkaline phosphatase (AP) was seen at Week 2 after the start of the study intervention. From Week 4 onward, the values remained relatively stable until the end of intervention at Week 12. All changes were reversible and returned to baseline levels by the safety follow-up visit—approximately 38 days after the end of the intervention. The clinical relevance of this finding and the origins of the increase (i.e., liver vs. bone) are unclear in the absence of a concurrent increase in the mean ALT, AST, bilirubin, or GGT values. In total, 4 participants (10.3%) in the eliapixant 25 mg BID arm, 3 participants (7.9%) in the eliapixant 75 mg BID arm, 1 participant (2.6%) in the eliapixant 150 mg BID arm, 2 participants (5.4%) in the placebo arm, and 3 participants in the elagolix 150 mg arm reported TEAEs associated with the Standardized MedDRA Query “Drug-related hepatic disorders”. One participant in the eliapixant 150 mg BID arm experienced a drug-induced liver injury, reported as a suspected unexpected serious adverse reaction (SUSAR). The 44-year-old study participant was diagnosed with “liver function test increased” (AST 4.8-fold upper limit of normal [ULN], ALT 7.5-fold ULN) at her regular visit after 4 weeks of treatment with the study drug; normal values had been recorded at screening and baseline and slightly increased values at Week 2 after the start of treatment. Unblinding revealed that the patient had received a dose of 150 mg BID eliapixant. Other liver parameters remained within normal ranges. Treatment with the study drug was discontinued immediately. This patient reported malaise and edema starting 3 weeks after the treatment began. She recovered from her symptoms and her transaminases returned to normal 2 weeks (AST) and 4 weeks (ALT) after the treatment ended. A detailed analysis of alternative causes of this patient’s moderate liver injury, based on the Food and Drug Administration 2009 Drug-Induced Liver Injury Guideline [ 36 ], found that she was reactive for anti-hepatitis A virus (HAV) immunoglobulin M (IgM) antibodies at baseline and at 2, 4, and 6 weeks thereafter as a potential alternative cause. However, no HAV ribonucleic acid or anti-HAV immunoglobulin G (IgG) antibodies were detected in serum at any point in time (unfortunately, no stool sample was collected or analyzed). Furthermore, no anti-HAV IgG antibodies were detected until 10 weeks after the first anti-HAV IgM antibodies were found; earlier detection would be expected during the course of a typical HAV infection. The totality of data gathered to clarify the causality of this case did not support a recent acute infection by HAV. In conclusion, the case was assessed by an external hepatology expert as an acute hepatocellular liver injury of moderate severity, based on the associated symptoms. The suggestive chronology and the absence of any other causes with clear potential made eliapixant the most likely cause of the liver injury.
A mean and median increase in antithrombin activity was observed in the eliapixant arms but not in the placebo arm, in line with similar findings from other phase 1 and 2 studies with eliapixant [ 37 , 38 , 39 ]. However, no differences were observed in TEAEs involving bleeding between the treatment arms.
A mean increase in fibrinogen was seen in the eliapixant arms, but not in the placebo arm, confirming a similar finding in other phase 2 studies with eliapixant [ 38 , 39 ]. The clinical relevance remains unclear, as there was no difference between eliapixant and the placebo regarding potential clinical manifestations of such changes, e.g., frequency of TEAEs involving bleeding or thromboembolic events.
Six participants reported a pregnancy during this study: 2 in the placebo arm and 1 in the elagolix 150 mg arm. Three participants reported pregnancies conceived during treatment: 2 in the eliapixant 25 mg arm and 1 in the eliapixant 150 mg arm.
Endometriosis, a debilitating gynecologic condition affecting millions of women worldwide, poses significant challenges in both diagnosis and management. A general lack of awareness by women and healthcare providers results in a significant delay from when a woman first experiences symptoms until she eventually is diagnosed and treated. Despite its prevalence and profound impact on quality of life, there remains a critical need for further research and the development of more effective treatment options [ 40 ].
To date, none of the medical treatments have been able to cure the disease, most treatments are not suitable for long-term use due to side effects [ 41 ], and symptoms recur as soon as the medication is stopped. Hormone treatments for endometriosis include combined contraceptives, progestogens, GnRH agonists, GnRH antagonists, and aromatase inhibitors. All treatments lead to a clinically significant reduction in pain with a similar magnitude of the treatment effect. Symptoms return after cessation of treatment and all hormones used to manage endometriosis have unwanted side effects [ 42 ]. Non-steroidal anti-inflammatory drugs are effective in reducing EAPP, but also have significant side effects, including gastric ulceration. Surgery can be effective to remove endometriosis lesions and scar tissue, but success rates are dependent on the extent of disease and the surgeon’s skills.
The SCHUMANN study aimed to assess the efficacy and safety of three different doses of eliapixant, in comparison with a placebo and elagolix 150 mg, in women with symptomatic endometriosis. The study was terminated prematurely, due to liver safety concerns; as a result, less than 50% of the planned number of participants completed the study.
Reductions in mean worst EAPP were observed at Week 12 in all treatment groups; no significant differences were observed across the treatment arms or compared with a placebo. At end of the intervention (Week 12), the mean (SD) changes in mean worst EAPP from baseline were − 1.56 (1.35) in the eliapixant 25 mg BID arm, − 2.21 (2.66) in the eliapixant 75 mg BID arm, − 1.88 (2.03) in the eliapixant 150 mg BID arm, and − 1.89 (1.91) in the placebo arm (primary per-protocol set). Only the elagolix 150 mg arm achieved better pain reduction than the other treatment arms of − 2.83 (2.38) (full-analysis set). The observed efficacy of elagolix was in line with expectations.
No significant dose-response model was found at any time. As no statistically significant or clinically relevant differences were observed between the treatment groups, this study did not meet its primary objective.
Due to the low percentage of women who completed the study, it was not considered meaningful to carry out subgroup analyses, for example with regard to hair and eye color.
No new safety signals were observed in relation to the known safety profile of eliapixant, which was generally well tolerated in this study. More participants experienced TEAEs in the eliapixant 150 mg BID, placebo, and elagolix 150 mg arms than in the two lower-dosed eliapixant treatment arms; no specific event caused this difference between the treatment arms.
Increases were observed in mean antithrombin activity, fibrinogen, and AP, confirming similar findings from other phase 2 studies with eliapixant [ 37 , 38 , 39 ]. The clinical relevance of these findings remains unclear, as there was no difference between eliapixant and the placebo with regard to clinical manifestations of these changes (e.g., TEAEs related to bleeding or thromboembolic events). Taste-related AEs were observed only in the eliapixant 150 mg BID (6 participants, 15.8%) and placebo (2 participants, 5.4%) arms.
The one observed case of moderate, probably drug-induced liver injury in a SCHUMANN participant receiving eliapixant 150 mg BID was the second case in the eliapixant phase 2 program with the following indications: RUCC, DNP, OAB, and EAPP. The first case occurred in a 26-year-old female participant after 4 weeks of exposure to eliapixant 150 mg BID in the phase 2b study of patients suffering from RUCC [ 38 ]. Although increases in liver function parameters with eliapixant treatment had been defined as a potential risk before the start of phase 2 studies, the benefit-risk ratio for the SCHUMANN study was no longer considered positive following two cases of moderate drug-induced liver injury of hepatocellular origin in participants exposed to eliapixant for 8–12 weeks of treatment during the phase 2 program in all indications and considering the totality of liver-safety data from the phase 2 program. The study was therefore put on clinical hold with an immediate stop of treatment and enrollment.
The strengths of SCHUMANN include its baseline demographics, which largely reflect those seen in a typical endometriosis population. The recruitment of participants across 20 countries meant that the results were likely to reflect the global population of patients with endometriosis. The limitations of the study include its premature termination, which resulted in less than 50% of the planned number of completers.
In summary, the SCHUMANN study did not show any significant differences in mean worst EAPP reductions at Week 12 across various treatment arms or compared with a placebo. The tolerability profile of eliapixant was consistent with that observed in other phase 2 studies of the program. However, the benefit-risk ratio for this study was no longer considered positive following the second case of a moderate, probably drug-induced liver injury in a participant receiving eliapixant 150 mg BID in the phase 2 program. The study was terminated prematurely; subsequently, Bayer AG discontinued the entire development program in all indications.
Overall, there is need for further research in the fields of new treatment options and early diagnosis of endometriosis, particularly in young patients.
The availability of data underpinning this publication will be determined in accordance with Bayer’s commitment to the European Federation of Pharmaceutical Industries and Associations and Pharmaceutical Research and Manufacturers of America and their principles for responsible clinical trial data sharing, pertaining to scope, timepoint, and the data access process. At the request of qualified scientific and medical researchers, Bayer commits to sharing patient-level clinical trial data, study-level clinical trial data, and protocols from patient clinical trials of medicines and indications approved in the US and European Union, as required for legitimate research. This commitment applies to data on new medicines and indications approved by the European Union and US regulatory agencies on or after January 1, 2014. Interested researchers can use www.clinicalstudydatarequest.com to request access to anonymized patient-level data and supporting documents from clinical studies in order to carry out further research to advance medical science or improve patient care. Alternatively, researchers may contact Susanne Parke (Research and Development, Bayer AG, Berlin, Germany; [email protected]). Information on the Bayer criteria for listing studies and other relevant information is provided in the study sponsors section of the portal. Access will be granted to anonymized patient-level data, protocols, and clinical study reports following approval by an independent scientific review panel. Bayer is not involved in the decisions made by the independent review panel and will implement all necessary measures to safeguard patient privacy.
No datasets were generated or analyzed during the current study.
Adverse event
Alanine aminotransferase
Alkaline phosphatase
Aspartate aminotransferase
Adenosine triphosphate
Twice daily
Body mass index
Confidence interval
Diabetic neuropathic pain
Electronic handheld diary
End of intervention
Endometriosis symptom diary
Gamma-glutamyl transferase
Gonadotrophin-releasing hormone
Anti-hepatitis A virus
Immunoglobulin G
Immunoglobulin M
Least squares
Multiple comparison procedure modeling
Medical Dictionary for Regulatory Activities
Non-menstrual pelvic pain
Numeric rating scale
Overactive bladder
Patient-reported outcome
Preferred term
Refractory or unexplained chronic cough
Serious adverse event
Standard deviation
Treatment-emergent adverse event
Upper limit of normal
Zondervan KT, Becker CM, Koga K, Missmer SA, Taylor RN. Viganò P. Endometriosis. Nat Rev Dis Primers. 2018;4(1):9.
Article PubMed Google Scholar
Bulun SE, Yilmaz BD, Sison C, Miyazaki K, Bernardi L, Liu S, et al. Endometriosis. Endocr Rev. 2019;40(4):1048–79.
Article Google Scholar
Marquardt RM, Kim TH, Shin JH, Jeong JW. Progesterone and estrogen signaling in the endometrium: what goes wrong in endometriosis? Int J Mol Sci. 2019;20(15):3822.
Article CAS PubMed PubMed Central Google Scholar
Chapron C, Marcellin L, Borghese B, Santulli P. Rethinking mechanisms, diagnosis and management of endometriosis. Nat Rev Endocrinol. 2019;15(11):666–82.
Nnoaham KE, Hummelshoj L, Webster P, D’Hooghe T, de Cicco Nardone F, de Cicco Nardone C, et al. Impact of endometriosis on quality of life and work productivity: a multicenter study across ten countries. Fertil Steril. 2011;96(2):366–e738.
Article PubMed PubMed Central Google Scholar
Simoens S, Dunselman G, Dirksen C, Hummelshoj L, Bokor A, Brandes I, et al. The burden of endometriosis: costs and quality of life of women with endometriosis and treated in referral centres. Hum Reprod. 2012;27(5):1292–9.
Soliman AM, Yang H, Du EX, Kelley C, Winkel C. The direct and indirect costs associated with endometriosis: a systematic literature review. Hum Reprod. 2016;31(4):712–22.
Eisenberg VH, Weil C, Chodick G, Shalev V. Epidemiology of endometriosis: a large population-based database study from a healthcare provider with 2 million members. BJOG. 2018;125(1):55–62.
Article CAS PubMed Google Scholar
Dunselman GA, Vermeulen N, Becker C, Calhaz-Jorge C, D’Hooghe T, De Bie B, et al. ESHRE guideline: management of women with endometriosis. Hum Reprod. 2014;29(3):400–12.
Parasar P, Ozcan P, Terry KL. Endometriosis: epidemiology, diagnosis and clinical management. Curr Obstet Gynecol Rep. 2017;6(1):34–41.
Ford AP. In pursuit of P2X3 antagonists: novel therapeutics for chronic pain and afferent sensitization. Purinergic Signal. 2012;8(Suppl 1):3–26.
Fabbretti E. ATP P2X3 receptors and neuronal sensitization. Front Cell Neurosci. 2013;7:236.
Bonvini SJ, Belvisi MG. Cough and airway disease: the role of ion channels. Pulm Pharmacol Ther. 2017;47:21–8.
North RA. P2X receptors. Philos Trans R Soc Lond B Biol Sci. 2016;371(1700):20150427.
Cockayne DA, Dunn PM, Zhong Y, Rong W, Hamilton SG, Knight GE, et al. P2X2 knockout mice and P2X2/P2X3 double knockout mice reveal a role for the P2X2 receptor subunit in mediating multiple sensory effects of ATP. J Physiol. 2005;567(Pt 2):621–39.
Burnstock G. Purinergic signalling: therapeutic developments. Front Pharmacol. 2017;8:661.
Yuan M, Ding S, Meng T, Lu B, Shao S, Zhang X, et al. Effect of A-317491 delivered by glycolipid-like polymer micelles on endometriosis pain. Int J Nanomed. 2017;12:8171–83.
Article CAS Google Scholar
Bernier LP, Ase AR, Séguéla P. P2X receptor channels in chronic pain pathways. Br J Pharmacol. 2018;175(12):2219–30.
Ryan NM, Vertigan AE, Birring SS. An update and systematic review on drug therapies for the treatment of refractory chronic cough. Expert Opin Pharmacother. 2018;19(7):687–711.
Laux-Biehlmann A, D’Hooghe T, Zollner TM. Menstruation pulls the trigger for inflammation and pain in endometriosis. Trends Pharmacol Sci. 2015;36(5):270–6.
McKinnon B, Bersinger NA, Wotzkow C, Mueller MD. Endometriosis-associated nerve fibers, peritoneal fluid cytokine concentrations, and pain in endometriotic lesions from different locations. Fertil Steril. 2012;97(2):373–80.
McKinnon BD, Bertschi D, Bersinger NA, Mueller MD. Inflammation and nerve fiber interaction in endometriotic pain. Trends Endocrinol Metab. 2015;26(1):1–10.
Wang G, Tokushige N, Russell P, Dubinovsky S, Markham R, Fraser IS. Hyperinnervation in intestinal deep infiltrating endometriosis. J Minim Invasive Gynecol. 2009;16(6):713–9.
Barcena de Arellano ML, Mechsner S. The peritoneum—an important factor for pathogenesis and pain generation in endometriosis. J Mol Med (Berl). 2014;92(6):595–602.
CAS PubMed Google Scholar
Bodin P, Burnstock G. Increased release of ATP from endothelial cells during acute inflammation. Inflamm Res. 1998;47(8):351–4.
Bodin P, Burnstock G. Evidence that release of adenosine triphosphate from endothelial cells during increased shear stress is vesicular. J Cardiovasc Pharmacol. 2001;38(6):900–8.
Burnstock G. Purinergic receptors and pain. Curr Pharm Des. 2009;15(15):1717–35.
Lazarowski ER, Shea DA, Boucher RC, Harden TK. Release of cellular UDP-glucose as a potential extracellular signaling molecule. Mol Pharmacol. 2003;63(5):1190–7.
Seitz C, Lanius V, Lippert S, Gerlinger C, Haberland C, Oehmke F, et al. Patterns of missing data in the use of the endometriosis symptom diary. BMC Womens Health. 2018;18(1):88.
Vitonis AF, Vincent K, Rahmioglu N, Fassbender A, Buck Louis GM, Hummelshoj L, et al. World endometriosis research foundation endometriosis phenome and biobanking harmonization project: II. Clinical and covariate phenotype data collection in endometriosis research. Fertil Steril. 2014;102(5):1223–32.
Missmer SA, Spiegelman D, Hankinson SE, Malspeis S, Barbieri RL, Hunter DJ. Natural hair color and the incidence of endometriosis. Fertil Steril. 2006;85(4):866–70.
Bretz F, Pinheiro JC, Branson M. Combining multiple comparisons and modeling techniques in dose-response studies. Biometrics. 2005;61(3):738–48.
European Medicines Agency (EMA). ICH E4 Dose response information to support drug registration. 1994. https://www.ema.europa.eu/en/ich-e4-dose-response-information-support-drug-registration . Accessed October 31, 2022.
European Medicines Agency (EMA). Qualification of MCP Mod as an efficient statistical methodology for model-based design and analysis of phase II dose finding studies under model uncertainty. 2014. https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/qualification-opinion-mcp-mod-efficient-statistical-methodology-model-based-design-analysis-phase-ii_en.pdf . Accessed June 14, 2022.
Taylor HS, Giudice LC, Lessey BA, Abrao MS, Kotarski J, Archer DF, et al. Treatment of endometriosis-associated pain with elagolix, an oral GnRH antagonist. N Engl J Med. 2017;377(1):28–40.
US Food and Drug Administration. Drug-induced liver injury: premarketing clinical evaluation. 2009. https://www.fda.gov/regulatory-information/search-fda-guidancedocuments/drug-induced-liver-injury-premarketing-clinical-evaluation
Ewerton F, Cruz F, Kapp M, Klein S, Roehm P, Chapple C. Efficacy and safety of eliapixant in overactive bladder: the 12-week, randomised, placebo-controlled phase 2a OVADER study. Eur Urol Focus. 2023;S2405–4569(23):00182–7.
Google Scholar
Dicpinigaitis PV, Morice AH, Smith JA, Sher MR, Vaezi M, Guilleminault L, et al. Efficacy and safety of eliapixant in refractory chronic cough: the randomized, placebo-controlled phase 2b PAGANINI study. Lung. 2023;201(3):255–66.
Bouhassira D, Tesfaye S, Sarkar A, Soisalon-Soininen S, Stemper B, Baron R. Efficacy and safety of eliapixant in patients with diabetic neuropathic pain: the randomized, placebo-controlled, double-blind, phase 2a PUCCINI study. Pain. 2024;165(4):785–95.
Becker CM, Bokor A, Heikinheimo O, Horne A, Jansen F, Kiesel L et al. ESHRE guidelines: endometriosis. Hum Reprod Open. 2022:1–26.
Rogers PAW, Adamson GD, Al-Jefout M, Becker CM, D’Hooghe TM, Dunselman GAJ, et al. Research priorities for endometriosis. Recommendations from a global consortium of investigators in endometriosis. Reprod Sci. 2017;24(2):202–26.
Horne A, Missmer S. Pathophysiology, diagnosis, and management of endometriosis. BMJ. 2022;379:e070750.
Download references
The authors would like to thank the investigators and participants for their involvement in the study.
Bayer AG funded the SCHUMANN study.
Authors and affiliations.
Research and Development, Bayer AG, Berlin, Germany
Susanne Parke & Katrin Roth
Pharmacovigilance, Bayer AG, Berlin, Germany
Kerstin Gude
Data Science UK, Bayer PLC, UK
Fabrizio Messina
You can also search for this author in PubMed Google Scholar
FM, KG, KR, and SP designed the study. All authors interpreted the data, wrote the manuscript, and approved the final version for publication.
Correspondence to Susanne Parke .
The Institutional Review Board/Independent Ethics Committee at each center approved the protocol. The study was carried out in accordance with Good Clinical Practice guidelines, the Declaration of Helsinki, and the Council for International Organizations of Medical Sciences International Ethical Guidelines. All participants provided written informed consent.
All authors have reviewed the final version of this manuscript and consented to its publication.
All authors are employees of Bayer AG.
Publisher’s note.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Below is the link to the electronic supplementary material.
Rights and permissions.
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ . The Creative Commons Public Domain Dedication waiver ( http://creativecommons.org/publicdomain/zero/1.0/ ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
Reprints and permissions
Cite this article.
Parke, S., Gude, K., Roth, K. et al. Efficacy and safety of eliapixant in endometriosis-associated pelvic pain: the randomized, placebo-controlled phase 2b SCHUMANN study. BMC Women's Health 24 , 353 (2024). https://doi.org/10.1186/s12905-024-03188-8
Download citation
Received : 05 December 2023
Accepted : 06 June 2024
Published : 19 June 2024
DOI : https://doi.org/10.1186/s12905-024-03188-8
Anyone you share the following link with will be able to read this content:
Sorry, a shareable link is not currently available for this article.
Provided by the Springer Nature SharedIt content-sharing initiative
ISSN: 1472-6874
IMAGES
VIDEO
COMMENTS
Participant observation is a type of observational study. Like most observational studies, these are primarily qualitative in nature, used to conduct both explanatory research and exploratory research. Participant observation is also often used in conjunction with other types of research, like interviews and surveys.
Case study research requires researchers to purposefully select information-rich cases, as they will allow researchers an in-depth understanding of relevant and critical issues under investigation (Patton, 1990, 2002).To gain such insights, purposive sampling is generally believed to contribute to the richness in the range of data collected and help increase the possibilities of uncovering ...
Although case studies have been discussed extensively in the literature, little has been written about the specific steps one may use to conduct case study research effectively (Gagnon, 2010; Hancock & Algozzine, 2016).Baskarada (2014) also emphasized the need to have a succinct guideline that can be practically followed as it is actually tough to execute a case study well in practice.
A case study is one of the most commonly used methodologies of social research. This article attempts to look into the various dimensions of a case study research strategy, the different epistemological strands which determine the particular case study type and approach adopted in the field, discusses the factors which can enhance the effectiveness of a case study research, and the debate ...
A case study is a research method that involves an in-depth examination and analysis of a particular phenomenon or case, such as an individual, organization, community, event, or situation. It is a qualitative research approach that aims to provide a detailed and comprehensive understanding of the case being studied.
Abstract. A case study enables s ocial researchers to examine the experiences of participants within a specific context in. detail. It involves a study of a particular case from which general ...
This study on an innovative secondary school in England shows how a "low-profile" participant-observer case study was crucial to the initial observation, the testing of hypotheses, the interpretive approach, and the grounded theory. Gilgun, J. F. (1994). A Case for Case Studies in Social Work Research. Social Work, 39, 4, 371-381.
"Participant observation is the central research method of ethnography. It requires a researcher to engage with people in as many different situations as possible to look at what people actually do as well as what they say they do (as in interviews or documents) in their everyday lives" - from EAR Training Handbook
A case study is an in-depth analysis of one individual or group. Learn more about how to write a case study, including tips and examples, and its importance in psychology. ... Participant observation: When the researcher serves as a participant in events and observes the actions and outcomes, it is called participant observation.
This SAGE case study demonstrates the practical application of participant observation as a research methodology, in its use by students during an undergraduate field-trip module. Participant observation requires researchers to engage in the "systematic description" of events and interactions, as framed by a research question, to produce a ...
A case study enables social researchers to examine the experiences of participants within a specific context in detail. It involves a study of a particular case from which general principles and rules can be drawn while relying on the analysis of the social context that reflects everyday experience. This article provides practical guidance on
The case study was designed as an ongoing participant observation and documentation of the design process and of the underlaying learning process, in which the author was engaged as reflective ...
As in the case of covert and passive participant observation, researchers do not run the risk that their presence alters the behavior of the groups they study through their interactions with them. However, the guinea pig effect is a problem for this form of observation, unlike the case of covert and passive participant observation, because the ...
Case Studies and Qualitative Reports Case studies and qualitative reports may have only a few participants or even a single participant. If there is space to do so, you can write a brief background of each participant in the "Participants" section and include relevant information on the participant's birthplace, current place of residence ...
The essential topics related to the selection of participants for a health research are: 1) whether to work with samples or include the whole reference population in the study (census); 2) the sample basis; 3) the sampling process and 4) the potential effects nonrespondents might have on study results. We will refer to each of these aspects ...
The above four examples of participant observation studies are all taken from Bryman's (2016) research methods book. Bryman ranges several studies (23 in total) on a scale ranging from 'full member' through to 'partially participating observer' down to 'non-participating observer with interaction'. Students might find it ...
Single-case (SC) studies have been identified by a variety of names, including "n of 1 studies" and "single-subject" studies. The term "single-case study" is preferred over the previously mentioned terms because previous terms suggest these studies include only one participant.
Case study research is an "…intensive study of a single ... documents included participant curriculum vitas and demographic information. Field notes written by the researcher provide a source of additional data noting observations of the setting and the participant.10 Observations of the university, the participant's office ...
As demonstrated above, there are various advantages to both idiographic and nomothetic single case study analyses - notably the empirically-rich, context-specific, holistic accounts that they have to offer, and their contribution to theory-building and, to a lesser extent, that of theory-testing.
The inclusion criteria should also address the capacity of the participant to understand the study goals, the study requirements (such as completing questionnaires and taking study medications), and the potential risks associated with joining a study. ... a case to exclude pregnant women could be made for studies with known risks to maternal ...
Participant and Nonparticipant Observation: A Study of Instructional Support Liaisons. The case presents an example of a research project in which the researchers struggled to negotiate participant and nonparticipant observation roles. The project and the data collection efforts including mistakes and eventual solutions are described.
The 20 completed case study participants were recruited through one of three hospices (9/20), a hospital team such as respiratory (5/20), their GP (3/20), a CN (2/20) or a community organisation (1/20). The central participant in the case could be a patient or FCG, who could then go on to nominate other key people.
Participant observation is a qualitative research method in which the researcher observes members of the group or community being researched and participates with them in their activities. This ...
Amy C. Edmondson is the Novartis Professor of Leadership and Management at Harvard Business School, a chair established to support the study of human interactions that lead to the creation of successful enterprises that contribute to the betterment of society.She has pioneered the concept of psychological safety for over 20 years and was recognized in 2021 as #1 on the Thinkers50 global ...
The newly appointed CEO of Highstreet Properties has doubts about several members of the top team she has inherited. She's trying to drive a turnaround, the company has a complicated matrix ...
The study initially involved 600 Black men - 399 with syphilis, 201 who did not have the disease. Participants' informed consent was not collected. ... In 1995, the program was expanded to include health, as well as medical, benefits. The last study participant died in January 2004. The last widow receiving THBP benefits died in January ...
Objective: There is a lack of evidence guiding treatment guidelines for individuals with comorbid complex posttraumatic stress disorder (C-PTSD) and binge eating disorder (BED). The article aims to present preliminary evidence to support the proof of concept of novel therapy termed meta-emotion therapy (MET) that targeted maladaptive beliefs about emotions, for this specific comorbidity ...
Section 10-4o - [Effective 10/1/2024] (Formerly Sec. 17-605). Family resource center program. Guidelines for programs. Study. Grants (a) The Department of Education, in conjunction with the Department of Social Services, shall coordinate a family resource center program to provide comprehensive child care services, remedial educational and literacy services, families-in-training programs and ...
The first case occurred in a 26-year-old female participant after 4 weeks of exposure to eliapixant 150 mg BID in the phase 2b study of patients suffering from RUCC . Although increases in liver function parameters with eliapixant treatment had been defined as a potential risk before the start of phase 2 studies, the benefit-risk ratio for the ...
Four blood samples were collected from each participant aseptically. The first blood sample (2 mL) was collected into a gel vacutainer tube and was centrifuged at 4000 r/min for 20 min after complete blood clotting. ... This case-control study included 100 adult HCV-positive patients with HCC and 100 matching adult HCV-positive patients with ...